Vinorelbine as first-line or second-line therapy for advanced breast cancer: A Phase I-II trial by the Danish Breast Cancer Co-operative Group

Acta Oncologica

Volumn 47, Issue 4, 2008, Pages 735-739

  Langkjer, Sven T ^a   Ejlertsen, Bent ^b   Mouridsen, Henning ^b   Andersen, Jørn ^c   Møller Nielsen, Mette ^d   Åge Møller, Knud ^e   Lindegaard Madsen, Ebbe ^f   Haarh, Vera ^g  

^a LILLEBAELT HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e Herning Centralsygehus ^*  (Denmark)

^f Sonderborg Hospital   (Denmark)

^g VIBORG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EPIRUBICIN; NAVELBINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; AUTONOMIC NEUROPATHY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; METASTASIS; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; TREATMENT RESPONSE; BREAST TUMOR; CANCER STAGING; DISEASE FREE SURVIVAL; DOSE RESPONSE; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; VINBLASTINE;

EID: 45149108308     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860801971421     Document Type: Article

References (9)

1. Hayes DF, Henderson IC. CAF in metastatic breast cancer: Standard therapy or another effective regimen? J Clin Oncol 1987;5:1497-9.
2. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, et al. Prospective randomized trial of docetacel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999;17:2341-54.
3. Cardoso F, Leo AD, Lohrisch C, Bernard C, Ferreira F, Piccart MJ. Second and subsequent lines of chemotherapy for metastatic breast cancer: What did we learn in the last two decades? Ann Oncol 2002;13:197-207.
4. Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993;11:1245-52.
5. Gasparini G, Caffo O, Barni S, Frontini L, Testolin A, Guglielmi RB, et al. Vinorelbine is an active antiproliferative agent in pre-treated advanced breast cancer patients: A phase II study. J Clin Oncol 1994;12:2094-101.
6. Bertsch LA, Donaldson G. Quality of life analyses from vinorelbine (Navelbine): Clinical trials of women with metastatic breast cancer. Semin Oncol 1995;22(Suppl 5):45-54.
7. Mathe G, Reizenstein P. Phase I pharmacological study of a new vinca alkaloid: Navelbine. Cancer Lett 1985;27:285-93.
8. Mano M. Vinorelbine in management of breast cancer: New perspectives, reviewed role in the era of targeted therapy. Cancer Treat Review 2006;32:106-18.
9. Degardin M, Bonneterre J, Hecquet B, Pion JM, Adenis A, Horner D, et al. Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 1994;5:423-6.